Suven Life Sciences (SUVEN) | Stock Overview & Key Data
Suven Life Sciences Performance Comparison
Stock Range
Today's Range
Low: ₹204.50
High: ₹211.00
on October 3, 2025
52 Week Range
Low: ₹102.50
High: ₹299.99
on February 28, 2025
on July 15, 2025
All-Time High: ₹338.50 on April 13, 2015
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR48.2B
EPS
-8.15
P/E Ratio (TTM)
-28.01
Forward P/E
10.55
P/B Ratio
40.49
PEG Ratio
-0.34
Div. Yield
N/A
ROE
-146.15%
Beta
0.858
Debt to Equity
0.00
Financial Highlights
Profitability
Gross Margin
100.00%
Operating Margin
-2,791.92%
Profit Margin
84.44%
Returns and Earnings
Return on Assets (TTM)
-118.91%
Return on Equity (TTM)
-146.15%
EBITDA
INR-1.9B
Net Income (TTM)
INR-1.8B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR0.34
Quarterly Revenue Growth (YoY)
85.60%
Quarterly Earnings Growth (YoY)
85.56%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Suven Life Sciences SUVEN | 48.20B Small-cap | -6.65% | -0.56% | -18.38% | 69.66% | 61.86% | 45.66% | 184.80% | 304.79% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | 0.56% | 4.66% | -1.86% | -3.66% | -13.43% | -14.34% | 71.30% | 219.01% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | -4.58% | -6.29% | -16.72% | 2.89% | -5.98% | 5.24% | 52.85% | 79.00% |
| Sequent Scientific SEQUENT | 48.13B Small-cap | -8.42% | 9.29% | -3.35% | 37.17% | 0.89% | -10.14% | 69.59% | 19.72% |
| Aarti Drugs AARTIDRUGS | 44.55B Small-cap | -5.64% | 3.08% | 3.92% | 42.25% | 7.15% | -5.48% | -1.60% | -50.42% |
| Gujarat Themis GUJTHEM | 43.84B Small-cap | -2.48% | 4.45% | 15.34% | 47.59% | 64.89% | 83.39% | 83.39% | 83.39% |
Ownership & Short Interest
Insider Ownership
68.81%
Institutional Ownership
2.09%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
185K
Average 90-Day Volume
147K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SUVEN's 52-week high and low?
- In the last 52 weeks, Suven Life Sciences reached a high of ₹299.99 (on July 15, 2025) and a low of ₹102.50 (on February 28, 2025).
- What is the market cap and P/E ratio for SUVEN?
- Curious about Suven Life Sciences's size and valuation? Its market capitalization stands at 48.20B. When it comes to valuation, the P/E ratio (trailing twelve months) is -28.01, and the forward P/E (looking ahead) is 10.55.
- Does SUVEN pay dividends? If so, what's the yield?
- As for dividends, Suven Life Sciences isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Suven Life Sciences's main competitors or similar companies to consider before investing?
When looking at Suven Life Sciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -14.34% 71.30% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic 5.24% 52.85% Sequent Scientific
SEQUENT48.13B Healthcare Drug Manufacturers - Specialty & Generic -10.14% 69.59% Aarti Drugs
AARTIDRUGS44.55B Healthcare Drug Manufacturers - Specialty & Generic -5.48% -1.60% Gujarat Themis
GUJTHEM43.84B Healthcare Drug Manufacturers - Specialty & Generic 83.39% 83.39% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Suven Life Sciences Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Suven Life Sciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -146.15%, the Debt to Equity ratio from the most recent quarter is 0.00, and its Gross Profit Margin stands at 100.00%.
- What is the recent revenue and earnings growth for SUVEN?
- Looking at Suven Life Sciences's growth, its revenue over the trailing twelve months (TTM) was INR75M. Compared to the same quarter last year (YoY), quarterly revenue grew by 85.60%, and quarterly earnings saw a YoY growth of 85.56%.
- How much of SUVEN stock is held by insiders and institutions?
- Wondering who owns Suven Life Sciences stock? Company insiders (like executives and directors) hold about 68.81% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 2.09%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.